The utility and management of vaginal cytology after treatment for endometrial cancer
- PMID: 23262937
- PMCID: PMC3864642
- DOI: 10.1097/aog.0b013e31827499a9
The utility and management of vaginal cytology after treatment for endometrial cancer
Abstract
Objective: To estimate the accuracy of vaginal cytology in postoperative surveillance for detecting recurrent endometrial cancer and to estimate the optimal management of squamous abnormalities detected in this setting.
Methods: This review included women who underwent hysterectomy for endometrial cancer between January 1, 2006, and December 31, 2010, and had at least one postoperative Pap test. Clinical and demographic data were collected and outcomes including abnormal vaginal cytology, results of colposcopic examination, and endometrial cancer recurrence were assessed. A Cox regression model to estimate the risk of abnormal cytology was created. Sensitivity, specificity, and negative and positive predictive values of detecting vaginal recurrences were calculated.
Results: Four hundred thirty-three women contributed 2,378 Pap tests. At least one abnormal cytology result was found during follow-up of 55 (13%) women, representing 3% of all Pap tests. No recurrent endometrial cancers were diagnosed on the basis of isolated abnormal cytology. No cases of recurrent cancer were diagnosed in women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion (LSIL) Pap test results. In multivariable analysis, abnormal cytology was highly associated with prior postoperative radiation therapy (P<.001). The sensitivity, specificity, and positive and negative predictive values of an abnormal Pap test result in detecting a local recurrence are 40%, 87.9%, 7.3%, and 98.4%, respectively.
Conclusion: Colposcopy is not needed after a Pap test result read as atypical squamous cells of undetermined significance or LSIL.
Level of evidence: III.
Similar articles
-
Vaginal Cytology Results in Follow-up of Endometrial Carcinoma After Hysterectomy.Am J Clin Pathol. 2016 Aug;146(2):244-7. doi: 10.1093/ajcp/aqw100. Epub 2016 Jun 30. Am J Clin Pathol. 2016. PMID: 27371362
-
Does Cytological Laboratory Holds the Responsibility for the Low Sensitivity of the PAP Test in Detecting Endometrial Cancer?Coll Antropol. 2015 Sep;39(3):713-7. Coll Antropol. 2015. PMID: 26898071
-
Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus.J Med Virol. 2002 Jul;67(3):401-5. doi: 10.1002/jmv.10077. J Med Virol. 2002. PMID: 12116034
-
Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: a nationwide cohort study.Am J Obstet Gynecol. 2017 Jan;216(1):48.e1-48.e15. doi: 10.1016/j.ajog.2016.07.042. Epub 2016 Jul 25. Am J Obstet Gynecol. 2017. PMID: 27457115
-
Cytomorphology of unusual primary tumors in the Pap test.Cytojournal. 2013 Aug 30;10:17. doi: 10.4103/1742-6413.117356. Cytojournal. 2013. PMID: 24082913 Free PMC article. Review.
Cited by
-
Major clinical research advances in gynecologic cancer in 2021.J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43. J Gynecol Oncol. 2022. PMID: 35245004 Free PMC article. Review.
-
Efficacy of Endometrial Cancer Follow-up Protocols: Time to Change?Rev Bras Ginecol Obstet. 2021 Jan;43(1):41-45. doi: 10.1055/s-0040-1721352. Epub 2021 Jan 29. Rev Bras Ginecol Obstet. 2021. PMID: 33513635 Free PMC article.
-
Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models.Gynecol Oncol. 2020 Mar;156(3):701-709. doi: 10.1016/j.ygyno.2019.12.036. Epub 2020 Jan 6. Gynecol Oncol. 2020. PMID: 31916980 Free PMC article. Review. No abstract available.
-
Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors.Obstet Gynecol. 2016 Mar;127(3):449-458. doi: 10.1097/AOG.0000000000001293. Obstet Gynecol. 2016. PMID: 26855104 Free PMC article.
References
-
- Creasman W, Miller D. Adenocarcinoma of the Uterine Corpus. In: Di Saia P, Creasman W, Mannel RS, McMeekin DS, Mutch DG, editors. Clinical Gynecologic Oncology. 8th ed. Philadelphia, PA: Elsevier Saunders; pp. 141–174.
-
- Creutzberg CL, van Putten WLJ, Koper PC, Lybeert MLM, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecologic Oncology. 2003 May 1;89(2):201–209. - PubMed
-
- Huh W, Straughn JM, Mariani A, Podratz KC, Havrilesky LJ, Alvarez Secord A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. International Journal of Gynecological Cancer. 2007 Jul.17(4):886–889. - PubMed
-
- Hasbini A, Haie-Meder C, Morice P, Chirat E, Duvillard P, Lhomme C, et al. Outcome after salvage radiotherapy (brachytherapy +/− external) in patients with a vaginal recurrence from endometrial carcinomas. Radiother Oncol. 2002 Oct.65(1):23–28. - PubMed
-
- Petignat P, Jolicoeur M, Alobaid A, Drouin P, Gauthier P, Provencher D, et al. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecologic Oncology. 2006 Jun.101(3):445–449. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
